Company intelligence / Profile preview

Resolute Ventures

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

RS-5, the lead candidate, has demonstrated potent single-agent anti-cancer efficacy in 22 preclinical studies across 10 tumor models and is well tolerated; advancing through IND-enabling studies.[2][4][8]

Therapeutic areas: Oncology
Modalities: Synthetic drug conjugateMacrophage-Targeted Conjugate (MAC-TAC)
Industry: Biotech

Beyond the preview

Go deeper on Resolute Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resolute Ventures.

Explore the full profile